Anesiva, Inc.

Quick facts

Phase 3 pipeline

• CGT003 (E2F Duplex Decoy) · Oncology
  CGT003 is a decoy oligonucleotide that binds and sequesters E2F transcription factors, blocking their ability to drive cell proliferation and survival.

Phase 1 pipeline

• NF-kappaB Decoy

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Anesiva, Inc. portfolio CI brief
• Anesiva, Inc. pipeline updates RSS